JP Morgan lifts Kiniksa Pharmaceuticals price target to $122 from $107
JP Morgan analysts raised their price target on Kiniksa Pharmaceuticals shares to $122 from $107, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan analysts raised their price target on Kiniksa Pharmaceuticals shares to $122 per share from $107. The information comes from Dow Jones Newswires.
The report also points to a Benzinga page that tracks analyst ratings for the KNSA stock.
why it matters
Price target changes are a common event in equity markets. They reflect an analyst's revised view of a stock, but on their own they do not set the direction of prices and are not a recommendation to buy or sell.
tags
instruments
sources
- Kiniksa Pharmaceuticals Price Target Raised to $122.00/Share From $107.00 by JP Morgan — Dow Jones Newswires, 30 October 2026 at 22:55 UTC
- T Rowe Price Price Target Raised to $107.00/Share From $106.00 by JP Morgan — Dow Jones Newswires, 30 October 2026 at 23:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗